Dysnatremia is a predictor for morbidity and mortality in hospitalized patients with COVID-19

Ploutarchos Tzoulis*, MD, PhD, MSc (Hons), MRCP; Julian A Waung*, BM, PhD; Emmanouil Bagkeris, MSc; Ziad Hussein, MD; Aiyappa Biddanda, MBBS, MRCP; John Cousins, BSc (Hons), MBChB; Alice Dewsnip, MBBS, BSc; Kanoyin Falayi; Will McCaughran, MBBS, BSc; Chloe Mullins, MBBS, BSc; Ammara Naeem, MBBS, MRCP; Muna Nwokolo, MBBS, BSc; Helen Quah; Syed Bitat, MRCP (UK); Eithar Deyab, MBBS, MD, MRCP; Swarupini Ponnampalam, MBBS, MRCP (UK); Pierre-Marc Bouloux, BSc, MBBS (Hons), MD, FRCP; Hugh Montgomery, MBBS, BSc, FRCP, MD; Stephanie E Baldeweg, MBBS, MD, FRCP

* Co-first authors (these authors contributed equally)

Department of Metabolism & Experimental Therapeutics, Division of Medicine, University College London, London, UK (Tzoulis); Department of Endocrinology & Diabetes, Whittington Health NHS Trust, London, UK (Tzoulis, Waung, Biddanda, Cousins, Dewsnip, Falayi, Mccaughran, Mullins, Naeem, Nwokolo, Montgomery); National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK (Bagkeris); Department of Diabetes & Endocrinology, University College London Hospital NHS Foundation Trust, London, UK (Hussein, Deyab, Bitat, Ponnampalam, Baldeweg); Centre for Neuroendocrinology, Royal Free Campus, University College London, London, UK (Bouloux); UCL Institute for Human Health and Performance, University College London, London, UK (Montgomery); Division of Medicine, University College London, London, UK (Hussein, Baldeweg)
All correspondence and requests for reprints should be addressed to: Dr Ploutarchos Tzoulis, MD, PhD, MSc (Hons), MRCP, Department of Metabolism & Experimental Therapeutics, Division of Medicine, University College London, Gower Street, WC1E 6BT, London, UK. E-mail Ploutarchos.tzoulis@nhs.net

Disclosure summary: The authors have nothing to disclose.
Abstract

**Background:** Dysnatremia is an independent predictor of mortality in patients with bacterial pneumonia. There is paucity of data about the incidence and prognostic impact of abnormal sodium concentration in patients with coronavirus disease 19 (COVID-19).

**Methods:** This retrospective longitudinal cohort study, including all adult patients who presented with COVID-19 to two hospitals in London over an 8-week period, evaluated the association of dysnatremia (serum sodium < 135 or > 145 mmol/L, hyponatremia and hypernatremia, respectively) at several timepoints with inpatient mortality, need for advanced ventilatory support and acute kidney injury (AKI).

**Results:** The study included 488 patients (median age 68 years). At presentation, 24.6% of patients were hyponatremic, mainly due to hypovolemia, and 5.3% hypernatremic. Hypernatremia two days after admission and exposure to hypernatremia at any timepoint during hospitalization were associated with a 2.34-fold (95% CI 1.08 – 5.05, p=0.0014) and 3.05-fold (95% CI 1.69 – 5.49, p<0.0001), respectively, increased risk of death compared to normonatremia. Hyponatremia at admission was linked with a 2.18-fold increase in the likelihood of needing ventilatory support (95% CI 1.34-3.45, p= 0.0011). Hyponatremia was not a risk factor for inhospital mortality, except for the subgroup of hypovolemic hyponatremia. Sodium values were not associated with the risk for AKI and length of hospital stay.
Conclusion:
Abnormal sodium levels during hospitalization are risk factors for poor prognosis, with hypernatremia and hyponatremia being associated with a greater risk of death and respiratory failure, respectively. Serum sodium values could be used for risk stratification in patients with COVID-19.

Keywords: COVID-19, SARS-CoV-2, SIADH, hyponatremia, hypernatremia, sodium
Introduction

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection represents the greatest global public health crisis of this generation\(^1\). Risk stratification at the time of hospital presentation is essential in order to allow early identification of patients at high risk of death and effective allocation of health resources\(^2\)\(^3\)\(^4\)\(^5\). Older age, male sex, Black or Asian ethnicity, and the presence of diabetes mellitus, obesity or ischemic heart disease (IHD) are well-established risk factors for excess mortality in COVID-19\(^6\)\(^7\)\(^8\)\(^9\). Elevated biomarkers, such as white cell count, neutrophil count, C-reactive protein (CRP), urea, creatinine, transaminases, cardiac troponin I and D-dimer, as well as low lymphocyte count and hypoalbuminemia are associated with excess in-hospital mortality\(^10\)\(^11\)\(^12\). Recent studies have added elevated serum cortisol\(^13\) and hyperglycemia\(^14\) at admission as independent predictors of mortality in patients with COVID-19.

Hypernatremia (serum sodium > 145 mmol/L) and hyponatremia (serum sodium < 135 mmol/L) are independent risk factors for excess mortality in hospitalized patients\(^15\)\(^16\)\(^17\)\(^18\)\(^19\)\(^20\). Hypernatremia is rare among patients with community-acquired pneumonia (CAP), but can occur when significant renal water loss is corrected with too little water or relatively hypertonic fluids\(^15\) and is independently associated with mortality\(^21\). Hyponatremia is the most common electrolyte abnormality in patients with bacterial pneumonia, is usually attributed to the syndrome of inappropriate antidiuresis (SIAD) or hypovolemia, and predicts poor outcome\(^21\)\(^22\)\(^23\)\(^24\). Infection can cause excess release of pro-inflammatory
cytokines, such as interleukin-1β (IL-1β) and interleukin-6 (IL-6), which induce non-osmotic release of arginine vasopressin (AVP), causing hyponatremia due to SIAD\textsuperscript{25, 26}. Therefore, hyponatremia is a good surrogate marker of the degree of inflammatory response, reflecting the severity of various infections\textsuperscript{27}. Neither the extent to which the relationship between hyponatremia and poor outcome is causal, nor the impact of correcting serum sodium, are known\textsuperscript{28, 29}.

Recent observational data suggest that hyponatremia is common in COVID-19 patients on hospital admission and associated with poor clinical outcome\textsuperscript{30, 31, 32}. However, longitudinal data such as ours remain lacking. Our primary objective was to examine the association of serum sodium during hospitalization with key clinical outcomes, including mortality, need for advanced respiratory support and Acute Kidney Injury (AKI). Our secondary objective was to explore the role of serum sodium as a marker of inflammatory response in COVID-19, by evaluating the longitudinal relationship between sodium and CRP concentration.

**Methods**

**Study design and population**

This retrospective longitudinal cohort study was undertaken in two inner city hospitals in London, the Whittington Hospital (hospital A) and University College London Hospital NHS Foundation Trust, UCLH (hospital B). The study was approved by the governance team and institutional ethics board of hospitals A and B, respectively. The study included all consecutive patients aged 16 years or older who were admitted to hospitals A and B between February and May 2020 and who had a
positive real-time reverse transcriptase–polymerase chain reaction (RT-PCR) test for SARS-CoV-2 on nasopharyngeal swab or other specimen.

**Data collection**

Data were obtained from electronic medical records, pathology records and discharge summaries. Demographic characteristics, comorbidities, hematological and biochemical laboratory results on admission, radiological findings, and data relating to respiratory, cardiological and renal complications was collected. Results of four biochemical variables (serum sodium, urea, creatinine and CRP) were collected longitudinally on the day of presentation (day 1), on day 3 (± 24 hours), on day 6 (± 24 hours), on day 11 (± 48 hours), on day 18 (± 48 hours), as well as on the day of admission to intensive care unit (ICU), the day of lowest and highest serum sodium concentration, and on the day of the last sodium measurement within 48 hours prior to discharge or death. The change in serum sodium between day 6 and day 1 was defined as 5-day delta sodium and was divided into four groups (≤ -3, -2 to +2, +3 to +7 and ≥ +8 mmol/L), according to the magnitude of change. Main outcome measures were inpatient mortality, need for advanced respiratory support, defined as continuous positive airway pressure (CPAP) or intubation and invasive mechanical ventilation (IMV), and AKI.

When blood glucose exceeded 10 mmol/L on presentation, serum sodium concentration was corrected for hyperglycemia. For glucose values between 10-22.1 mmol/L or ≥ 22.2 mmol/L, we used a correction factor of a 1.6 or 2.4 mmol/L, respectively, decrease in sodium concentration per 5.6 mmol/L increase in glucose value above 10 mmol/L\(^3\). Serum sodium was measured on days 1, 3, 6, 11, 18 to
determine changes to sodium status longitudinally. Accordingly, serum sodium status was stratified into 3 categories: 135-145 mmol/L, normal as per the laboratory reference ranges; <135 mmol/L (hyponatremia) and >145 mmol/L (hypernatremia). Hyponatremia was further classified into mild (130-134 mmol/L) and moderate to severe (<130 mmol/L).34

Chronic kidney disease (CKD) prior to admission was defined as the most recent estimated glomerular filtration rate (eGFR) within 12 months pre-admission at <60 ml/min. A diagnosis of chronic hyponatremia was established if the last sodium value within 12 months pre-admission was <135 mmol/L. AKI was diagnosed and classified based on Kidney Disease: Improving Global Outcomes (KDIGO) definitions using the peak creatinine during hospitalization and last creatinine value pre-admission.35 The etiology of hyponatremia was ascertained through the results of laboratory investigations, including serum osmolality, spot urinary osmolality and sodium, serum cortisol and thyrotropin.36 In the absence of those data, plasma urea was used to discriminate euvoletic from hypovolemic hyponatremia since plasma urea value > 5 mmol/L has a predictive power of 80% for hypovolemic hyponatremia, while urea < 5 mmol/L indicates euvoletic hyponatremia in 80% of patients.37

**Statistical analysis**

Characteristics of the patients were expressed in frequencies and percentages when categorical and in median and interquartile range (IQRs) when continuous. Kaplan Meier survival curves were produced for serum sodium on day 3 of hospitalization as well as for exposure to abnormal sodium at any point during hospitalization. Pearson’s Chi-square test was used to compare mortality rates between 5-day delta sodium groups as well as rates of death, respiratory support and AKI between
longitudinal sodium status groups. Mann Whitney test was used to study the association of serum sodium concentrations on day 1, 3, 6, 11 or 18 with survival rate, need for advanced respiratory support, and AKI. Mann Whitney test with Bonferroni correction was used to study the association between laboratory results at presentation with survival. Cox proportional hazard models with time varying covariates were used to assess the association of sodium concentrations at day 1, 3 and 6 with in-hospital death. A-priori confounders considered in the multivariable analysis were: age, gender, ethnicity, smoking status, number of comorbidities, urea and CRP levels. The Friedman test was used to assess the change of sodium and urea over time and the Pearson correlation coefficient assessed their relationship. Univariable linear mixed effect models were used to explore whether the levels of sodium and urea during hospitalization were significantly different between the group of survivors and non-survivors. P-value < 0.05 was considered statistically significant. Prism 8 (Graphpad) and Stata 16 (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC) were used for statistical analysis.

Results
Baseline characteristics
This study included 488 patients, 277 males (56.8%) and 211 females (43.2%), with a median age of 68 years (Table 1). The commonest comorbidities were hypertension (45.7%), diabetes mellitus (25%), CKD (16.4%), asthma (11.9%), IHD (11.3%), cerebrovascular disease (8.6%), arrhythmia (8.6%), active cancer (8%), and chronic obstructive pulmonary disease (COPD) (8%). According to the most recent sodium levels preceding hospital admission, 5.1% of individuals had pre-
existing hyponatremia. Increased mortality was associated with advanced age, male
gender, smoking, pre-existing CKD, chronic hyponatremia and the presence of
active malignancy. Non-survivors had significantly higher concentrations of BUN,
creatinine, CRP and troponin, but lower concentrations of lymphocyte count and
albumin compared to survivors.

**Incidence and etiology of dysnatremia**

At hospital presentation, 26 individuals (5.3\%) had hypernatremia with a median
plasma urea value of 12.4 mmol/L. The incidence of hyponatremia at the time of
hospital presentation was higher at 24.6\%, including 18.4\% with mild and 6.2\%
moderate to severe hyponatremia, with a median urea concentration of 5.6 mmol/L.
Only 19\% of patients with serum sodium < 130 mmol/L underwent appropriate
laboratory work-up for the etiology of hyponatremia. Of those, based on urinary
sodium cut-off of 30 mmol/L, three quarters were classified as hypovolemic
hyponatremia and one quarter as non-hypovolemic hyponatremia. For the remaining
hyponatremic cases, using the cut-off value of 5 mmol/L for urea concentration,
55.7\% were classified as probable hypovolemic and 44.3\% non-hypovolemic
hyponatremia.

**Association between dysnatremia and mortality**

Serum sodium at presentation did not differ between survivors (median, IQR) (137,
135-140 mmol/L) and non-survivors (138, 134-141 mmol/L). Stratified by sodium
status at admission, the mortality rate for normonatremic, hyponatremic and
hypernatremic patients was 28.4\%, 30.8\% and 46.1\%, respectively. Those results
indicated a strong trend towards higher mortality rate in patients with baseline
hypernatremia, despite the difference not being statistically significant (p=0.07).

Among 120 patients who presented with hyponatremia, 31 individuals who either had only one measurement of serum sodium or developed at any stage hypernatremia were excluded in order to assess the impact of normalization of hyponatremia on patient outcomes. Comparison of 54 hyponatremic patients who had their sodium corrected with 35 patients who remained persistently hyponatremic did not show a significant difference in the in-hospital mortality rate (25.9 % versus 31.4 %, p=0.57).

Multivariable analysis identified three independent risk factors for higher in-hospital mortality; older age (adjusted hazard ratio=1.04, 95% CI 1.01 - 1.07, p=0.007), higher CRP concentrations (adjusted hazard ratio=1.10 per 20 mg/l, 95% CI 1.04 - 1.17, p<0.001), and hypernatremia at any time point during the first five days of hospitalization (adjusted hazard ratio=2.74, 95% CI 1.16 - 6.40, p=0.02) (Table 2). Hypernatremia on day 3 and on day 6 predicted mortality with an estimated hazard ratio of 2.34 (95% CI 1.08 – 5.05, p=0.0014) and 2.40 (95% CI 1.18 - 4.85, p=0.0011), respectively, whereas hyponatremia was not associated with death (Figure 1).

A longitudinal analysis of sodium data during hospital stay classified patients into four groups; 37.9% of patients remained normonatremic throughout hospitalization, 36.9% had exposure to hyponatremia, 10.9% were exposed to hypernatremia, and 14.3% experienced both hypernatremia and hyponatremia. The in-hospital mortality rate of patients who remained continuously normonatremic was 21.1%. Exposure to hypernatremia or both hypernatremia and hyponatremia were associated with significantly increased mortality rate of 56.6% (p<0.0001, odds ratio 3.05, 95% CI 1.69-5.49) and 45.7% (p=0.0038, odds ratio 2.25, 95% CI 1.33-3.82) respectively,
compared to normonatremia (Figure 2). Finally, patients exposed to hyponatremia had a mortality rate of 28.3% which was not significantly different compared to that of normonatremic individuals (p=0.16, odds ratio 1.34, 95% CI 0.89–2.04). However, the subgroup of patients who developed hypovolemic hyponatremia at any time point had a mortality rate of 40.9%, significantly higher than 21.1% of normonatremic individuals (p=0.0017, odds ratio 2.59, 95% CI 1.44 – 4.81).

**Longitudinal changes in sodium and urea levels and risk of death**

There was a progressive rise in median (IQR) serum sodium levels during hospitalization from a baseline of 137 (134 140) mmol/L to 141 (138 - 143) mmol/L on day 18 (p<0.001). A similar trend was observed with median serum urea (IQR) which increased from a baseline of 6.2 (4.0 10.6) mmol/L to 7.2 (4.7-11.5) mmol/L on day 18 (p=0.01) (Figure 3). However, sodium and urea levels were not correlated with a correlation coefficient r of 0.19.

Linear mixed effect models suggested that both sodium (p=0.02) and urea levels (p<0.001) were significantly higher over the hospitalization period among non-survivors compared to survivors (Figure 4). During first five days of hospital stay, median sodium levels increased in non-survivors from a baseline of 138 mmol/L to 141 mmol/L and in survivors from a baseline value of 137 mmol/L to 138 mmol/L.

With respect to urea, non-survivors had a high baseline median urea concentration of 8.8 mmol/L which decreased to 8.2 mmol/L after five days, while non-survivors had a starting urea value of 5.4 mmol/L which increased to 5.9 mmol/L over this time period. The incidence of hyponatremia decreased from 24.6% at admission to 14.1% five days later, while the frequency of hypernatremia rose from 5.3% to 13.8%. The
highest mortality rate was observed in patients with the largest 5-day increase in sodium (≤ -3 mmol/L, 34.5%; -2 to +2 mmol/L, 17.5%; +3 to +7 mmol/L, 26.3%; ≥ 8 mmol/L, 54.8%; p <0.005). The value of the last serum sodium measurement prior to discharge or death was significantly higher in non-survivors compared to survivors (141 vs 139 mmol/L, p < 0.005), with a 29.6% rate of hypernatremia in non-survivors compared to 5.2% in survivors.

**Hyponatremia is a prognostic factor for respiratory support, but not for length of stay and AKI**

Among 120 patients with hyponatremia at admission, 31.7% received advanced respiratory support compared to 17.5% and 7.7% of those with normonatremia or hypernatremia, respectively. Therefore, hyponatremia at admission is linked with a 2-fold increase in the likelihood of needing ventilatory support (p= 0.0011, odds ratio 2.18, 95% CI 1.34-3.46). The median serum sodium on presentation was significantly lower in patients who required CPAP or IMV (136 mmol/L) than in those who did not (138 mmol/L); p < 0.01. Of note, hypernatremia was not associated with an increased likelihood to need respiratory support, since the percentage of patients exposed to hypernatremia at any time point during hospitalization who required advanced ventilatory support was 16.7 %, not significantly different from 12.4 % of normonatremic patients (p=0.39, odds ratio 1.44, 95% CI 0.59 – 3.30). A total of 100 patients (20.5%) received additional ventilatory support, with 51 (10.5%) requiring CPAP, 25 patients (5.1%) requiring IMV, and 24 (4.9%) requiring both.

The in-hospital mortality rate of our cohort was 31.1% with a median time to death of 7 days, while survivors had a median length of stay of 8 days. Amongst 62 patients (12.7%) being admitted to ICU, 43.5% died and the median length of ICU stay was
14 days. Cardiac complications were documented in 6.8% of patients, including tachyarrhythmia (3.9%), decompensated heart failure (1.6%) and acute coronary syndrome (1.2%). In addition, venous thromboembolism was relatively common, with an occurrence rate of 3.9% for pulmonary embolism and 1.2% for deep venous thrombosis.

AKI occurred in 181 patients (37.1%), including 104 (21.3%) with stage 1, 36 (7.4%) with stage 2 and 41 (8.4%) with stage 3, while 3.1% of patients received renal replacement therapy. Serum sodium concentration at all timepoints was not related to the risk for AKI or length of hospital stay.

Median CRP values at presentation were significantly higher in non-survivors than in survivors (117 vs 72 mg/L, p<0.0001). At admission, median CRP values were similar, 78 mg/L, 82 mg/L, and 92 mg/L in hypo-, hyper-, and normonatremic patients. The lack of association between sodium and CRP values applied to all timepoints throughout hospitalization.

**Discussion**

This retrospective longitudinal cohort study of 488 inpatients with COVID-19 demonstrated a high prevalence for abnormal sodium of 29.9% at admission and 62.1% at any stage during hospitalization. Admission hyponatremia was common with an incidence of 24.6% and was usually classified as hypovolemic hyponatremia. Both hypernatremia and hyponatremia were risk factors for poor prognosis. Hypernatremia at any timepoint during hospitalization was a predictor of excess inpatient mortality. All types of hyponatremia were associated with significantly
increased risk for needing advanced ventilatory support, with hypovolemic hyponatremia also being a risk factor for in-hospital mortality.

The key novel finding of our study was that hospital-acquired hypernatremia, rather than hypernatremia at admission, was a predictor for in-hospital mortality, with the worst prognosis being reported in patients with the largest increase in serum sodium in the first 5 days of hospitalization. Hypernatremia reflects a deficit of total body water relative to total body sodium and is often accompanied by reduced extracellular fluid volume, highlighting hypovolemia as driver of mortality in COVID-19. The high frequency of volume depletion in COVID-19 illness might be explained by low oral intake due to anorexia or nausea, or significant increases in insensible fluid losses, or, less commonly, fluid losses due to diarrhea. Rehydration and volume repletion are thus often needed in such patients. However, conservative fluid regimens are sometimes applied as a component of lung-protective strategies, leading to the persistence or exacerbation of volume depletion. The contribution of diuretic use to hypernatremia should be limited since they are not routinely used in this context, as volume overload is not a common clinical feature in COVID-19 patients. Until more data are available and in line with the standard clinical approach in patients with other pathologies, an approach to fluid resuscitation which recognizes the frequency and severity of volume depletion, whilst taking appropriate care to prevent fluid overload or pulmonary oedema, should be strongly considered.

With respect to the prognostic impact of low serum sodium in COVID-19, this study showed that hyponatremia at hospital presentation was related to an increased likelihood to require advanced ventilatory support, consistent with the findings in other COVID-19 studies and studies in patients with CAP. The prognostic value
of hyponatremia might reflect a direct pathogenic impact, or association with increasing disease severity. Contrary to the independent association of hyponatremia with mortality in CAP, our study did not identify hyponatremia as a predictor of mortality in patients with COVID-19. However, in agreement with recent studies in general hospital populations, our data confirmed hypovolemic hyponatremia as a risk factor for excess mortality. This might be mediated through more severe disease in the former group, for instance, affecting salt-water loss through sweat or decreased dietary sodium intake in the context of insufficient water intake, or through the impacts of hypovolemia on circulatory homeostasis and end-organ function.

Interestingly, occurrence at hypernatremia at any time point during hospitalization was not associated with the need for advanced respiratory support. The contradictory findings in our cohort that patients with hypernatremia were more likely to die without greater use of advanced ventilatory support, while those with hyponatremia required more often respiratory support without having increased mortality, might be explained by selection bias. Hypernatremic patients might include the oldest and most frail who were not eligible for advanced ventilatory support. In contrast, patients with hyponatremia might be critically ill, but younger and with fewer comorbidities, and therefore responded to ventilatory support and survived.

Our study confirmed that AKI is common in inpatients with COVID-19, with a recorded prevalence of 36.9% prevalence, similar to the 36.6% in a large New York cohort. Since hypovolemia often contributes to development of AKI, it is surprising that abnormal serum sodium value was not a risk factor for AKI. Contrary to the well-established association of dysnatremia with length of hospitalization in CAP, our
study did not find any association between sodium levels and length of stay in COVID-19 patients.

Our longitudinal analysis of the potential link between sodium status and CRP levels did not find the inverse association which was observed in other inflammatory conditions\textsuperscript{25 26 44}. Two recent studies in patients with COVID-19 showed a significant relationship between elevated IL-6 levels and hyponatremia\textsuperscript{30 45}, supporting the concept of IL-6 related AVP release in a subpopulation of COVID-19 patients who are at risk of cytokine storm and subsequent adverse clinical outcomes\textsuperscript{46}. Therefore, hyponatremia might be used to identify the subgroup of COVID-19 patients who might benefit from targeted therapeutic approaches, such as IL-6 antagonists\textsuperscript{46}. The contradictory finding of our study that sodium concentration could not be used as a biomarker of the severity of inflammation might be explained by the heterogeneity of etiology of hyponatremia, with the majority of patients being classified as having hypovolemic hyponatremia and the remaining having probable SIAD. Therefore, our study cannot exclude the possibility that hyponatremia might be a surrogate marker of IL-6 secretion and degree of inflammatory response in the subgroup of SIAD patients.

Studies are promptly warranted in order to explore further the pathophysiological basis of dysnatremia in COVID-19 patients, its subtypes and its link with lung inflammation, severity of infection, and cytokine release. In addition, prospective intervention studies are required to determine whether correction of sodium abnormalities could improve clinical outcomes and establish the most effective fluid resuscitation strategy.

The main strength of this study is its longitudinal design, while all other observational studies have reported only admission data\textsuperscript{30 31 32}. Furthermore, this is the only study
which has evaluated the role of both hyponatremia and hypernatremia and has also collected data about the trajectory of natremia in combination with hydration status and inflammatory markers in order to explore their complex interaction. This study has several limitations. Firstly, the lack of electronic health records did not allow the authors to have detailed knowledge of medical treatment and fluid resuscitation strategies during hospitalization. Secondly, the lack of information about volume status and inadequate laboratory work-up did not allow us to accurately ascertain the etiology of hyponatremia. Thus, our population was heterogeneous, not allowing us to evaluate separately the impact of each subtype of hyponatremia on outcomes, which can differ substantially. In addition, our study did not include a control group of non-COVID-19 patients presenting with pneumonia, not allowing a direct comparison of the impact of hyponatremia between patients with and without COVID-19. Finally, the generalizability of some findings might be limited by the fact that our study took place in a time period characterized by unprecedented pressure on healthcare resources and little available knowledge about COVID-19.

Conclusions

Hypernatremia at any timepoint during hospital stay is related to excess in-hospital mortality, while hyponatremia at presentation is associated with a higher likelihood to require advanced ventilatory support. Hyponatremia was not a risk factor for in-hospital mortality, except for the subgroup of hypovolemic hyponatremia. Therefore, serum sodium values could be used in clinical practice to identify patients with COVID-19 at high risk of poor outcomes who would benefit from more intensive monitoring and judicious rehydration.
Acknowledgments

Author Contributions: Drs Tzoulis and Waung contributed equally as co-first authors. Drs Tzoulis and Waung had access to all the data in the study and take responsibility for the integrity of the data and the accuracy of data analysis.

Concept and design: Tzoulis, Waung.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Tzoulis, Waung.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Waung, Bagkeris.

Administrative, technical, or material support: Tzoulis, Waung, Bagkeris, Bouloux, Montgomery, Baldeweg.

Supervision: Tzoulis, Waung, Bagkeris, Bouloux, Montgomery, Baldeweg.

All authors revised the manuscript and approved the publication.

Data Availability: The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
References

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
2. Levy TJ, Richardson S, Coppa K, et al. Development and Validation of a Survival Calculator for Hospitalized Patients with COVID-19. medRxiv. 2020.
3. Liang W, Liang H, Ou L, et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern Med. 2020.
4. Wu G, Yang P, Xie Y, et al. Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study. Eur Respir J. 2020;56(2).
5. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020;370:m3339.
6. Pan D, Sze S, Minhas JS, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine. 2020;23:100404.
7. Grasselli G, Greco M, Zanella A, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020.
8. Gupta S, Hayek SS, Wang W, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med. 2020.
9. Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. J Clin Endocrinol Metab. 2020;105(8).
10. Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020.
11. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020.
12. Bannaga AS, Tabuso M, Farrugia A, et al. C-reactive protein and albumin association with mortality of hospitalised SARS-CoV-2 patients: A tertiary hospital experience. Clin Med (Lond). 2020;20(5):463-467.
13. Tan T, Khoo B, Mills EG, et al. Association between high serum total cortisol concentrations and mortality from COVID-19. Lancet Diabetes Endocrinol. 2020.
14. Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multicentre retrospective study. Diabetologia. 2020.
15. Hoorn EJ, Betjes MG, Weigel J, et al. Hypernatraemia in critically ill patients: too little water and too much salt. Nephrol Dial Transplant. 2008;23(5):1562-1568.
16. Lindner G, Funk GC, Schwarz C, et al. Hypernatremia in the critically ill is an independent risk factor for mortality. Am J Kidney Dis. 2007;50(6):952-957.
17. Eckart A, Hausfater P, Amin D, et al. Hyponatremia and activation of vasopressin secretion are both independently associated with 30-day mortality: results of a multicenter, observational study. J Intern Med. 2018;284(3):270-281.
18. Tzoulis P, Bagkeris E, Bouloux PM. A case-control study of hyponatraemia as an independent risk factor for inpatient mortality. Clin Endocrinol (Oxf). 2014;81(3):401-407.
19. Corona G, Giuliani C, Parenti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS One. 2013;8(12):e80451.
20. Cuesta M, Garrahy A, Slattery D, et al. Mortality rates are lower in SIAD, than in hypervolaemic or hypovolaemic hyponatraemia: Results of a prospective observational study. Clin Endocrinol (Oxf). 2017;87(4):400-406.
21. Kruger S, Ewig S, Giersdorf S, et al. Dysnatremia, vasopressin, atrial natriuretic peptide and mortality in patients with community-acquired pneumonia: results from the german competence network CAPNETZ. Respir Med. 2014;108(11):1696-1705.

22. Cuesta M, Slattery D, Goulden EL, et al. Hyponatraemia in patients with community-acquired pneumonia; prevalence and aetiology, and natural history of SIAD. Clin Endocrinol (Oxf). 2019;90(5):744-752.

23. Muller M, Schebold JC, Guignard V, et al. Hyponatremia is independently associated with in-hospital mortality in patients with pneumonia. Eur J Intern Med. 2018;54:46-52.

24. Zilberberg MD, Exuvides A, Spalding J, et al. Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study. BMC Pulm Med. 2008;8:16.

25. Park SJ, Oh YS, Choi MJ, et al. Hyponatremia may reflect severe inflammation in children with febrile urinary tract infection. Pediatr Nephrol. 2012;27(12):2261-2267.

26. Park SJ, Shin JI. Inflammation and hyponatremia: an underrecognized condition? Korean J Pediatr. 2013;56(12):519-522.

27. Swart RM, Hoorn EJ, Betjes MG, et al. Hyponatremia and inflammation: the emerging role of interleukin-6 in osmoregulation. Nephron Physiol. 2011;118(2):45-51.

28. Corona G, Giuliani C, Verbalis JG, et al. Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS One. 2015;10(4):e0124105.

29. Hoorn EJ, Zietse R. Hyponatremia and mortality: moving beyond associations. Am J Kidney Dis. 2013;62(1):139-149.

30. Frontera JA, Valdes E, Huang J, et al. Prevalence and Impact of Hyponatremia in Patients With Coronavirus Disease 2019 in New York City. Crit Care Med. 2020.

31. Tezcan ME, Dogan Gokce G, Sen N, et al. Baseline electrolyte abnormalities would be related to poor prognosis in hospitalized COVID-19 patients. New Microbes New Infect. 2020:100753.

32. Hu W, Lv X, Li C, et al. Disorders of sodium balance and its clinical implications in COVID-19 patients: a multicenter retrospective study. Intern Emerg Med. 2020.

33. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999;106(4):399-403.

34. Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatremia. Eur J Endocrinol. 2014;170(3):G1-47.

35. Ad-hoc working group of E, Fliser D, Laville M, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27(12):4263-4272.

36. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(Suppl 1):S1-S42.

37. Decaux G, Musch W. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol. 2008;3(4):1175-1184.

38. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003;17(4):471-503.

39. Chalmers JD, Singanayagam A, Hill AT. Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. Clin Infect Dis. 2008;47(12):1571-1574.

40. Cuesta M, Garrahy A, Slattery D, et al. Mortality rates are lower in siad, than in hypervolaemic or hypovolaemic hyponatraemia; results of a prospective observational study. Clin Endocrinol (Oxf). 2017.

41. Kutz A, Ebrahim F, Aghlmandi S, et al. Risk of Adverse Clinical Outcomes in Hyponatremic Adult Patients Hospitalized for Acute Medical Conditions: A Population-Based Cohort Study. J Clin Endocrinol Metab. 2020;105(11).

42. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-218.
43. Nair V, Niederman MS, Masani N, et al. Hyponatremia in community-acquired pneumonia. Am J Nephrol. 2007;27(2):184-190.
44. Beukhof CM, Hoorn EJ, Lindemans J, et al. Novel risk factors for hospital-acquired hyponatraemia: a matched case-control study. Clin Endocrinol (Oxf). 2007;66(3):367-372.
45. Berni A, Malandrino D, Parenti G, et al. Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together? J Endocrinol Invest. 2020.
46. Sinha P, Matthay MA, Calfee CS. Is a "Cytokine Storm" Relevant to COVID-19? JAMA Intern Med. 2020.
Legends for Figures and Tables

Table 1 - Patient characteristics at presentation

Table 2 – Univariable and multivariable associations of risk factors with in-hospital mortality among COVID-19 patients

Figure 1 – Probability of death based on serum sodium values 2 days after admission

Figure 2 - Probability of death based on history of abnormal serum sodium at any time during hospitalization

Figure 3 – The progression of median serum sodium and urea levels during hospital stay

Figure 4 – Median serum sodium and urea levels during hospitalization in survivors and non-survivors
### Tables

#### Table 1: Patient characteristics at presentation

|                  | Patients, Number (%) |   |   |   |
|------------------|----------------------|---|---|---|
|                  | Total                | Survived | Died |   |
|                  | 488 (100)            | 336 (68.9) | 152 (31.1) |   |
| Hospital         |                      |   |   |   |
| UCLH             | 117 (24.0)           | 80 (68.4) | 37 (31.6) |   |
| Whittington      | 371 (76.0)           | 256 (69.0) | 115 (31.0) |   |
| Sex              |                      |   |   | <0.005* |
| Female           | 211 (43.2)           | 149 (70.6) | 62 (29.4) |   |
| Male             | 277 (56.8)           | 187 (67.5) | 90 (32.5) |   |
| Age, years       |                      |   |   | <0.0001* |
| Group median (IQR) | 68 (56-80)    | 63 (52-76) | 79 (67-87) |   |
| ≤49              | 77 (15.8)            | 70 (90.9) | 7 (9.1) |   |
| 50-64            | 125 (25.6)           | 108 (86.4) | 17 (13.6) |   |
| 65-74            | 100 (20.5)           | 63 (63.0) | 37 (37.0) |   |
| 75-84            | 106 (21.7)           | 67 (63.2) | 39 (36.8) |   |
| ≥85              | 80 (16.4)            | 28 (35.0) | 52 (65.0) |   |
| Ethnicity        |                      |   |   | <0.0001* |
| White            | 211 (43.2)           | 147 (69.7) | 64 (30.3) |   |
| Black            | 85 (17.4)            | 63 (74.1) | 22 (25.9) |   |
| Asian            | 34 (7.0)             | 17 (17) | 17 (50) |   |
| Mixed            | 10 (2.1)             | 6 (60.0) | 4 (40.0) |   |
| Unknown          | 148 (30.3)           | 103 (69.6) | 45 (30.4) |   |
| Smoking status   | Smoking status | Smoking status | <0.05* |
|-----------------|----------------|----------------|--------|
| No              | 273 (55.9)     | 196 (71.8)     | 77 (28.2) |
| Current smokers | 24 (4.9)       | 14 (58.3)      | 10 (41.7) |
| Ex-Smokers      | 108 (22.1)     | 79 (73.1)      | 29 (26.9) |
| Unknown         | 83 (17)        | 47 (56.6)      | 36 (43.4) |

| Comorbidities   | Comorbidities | Comorbidities | Comorbidities |
|-----------------|---------------|---------------|---------------|
| Hypertension    | 223 (45.7)    | 156 (70.0)    | 67 (30.0)     | 0.63 |
| Diabetes        | 122 (25.0)    | 83 (68.0)     | 39 (32.0)     | 0.82 |
| stage 3-5 CKD   | 80 (16.4)     | 39 (48.8)     | 41 (51.3)     | 0.0016* |
| Asthma          | 58 (11.9)     | 42 (72.4)     | 16 (27.6)     | 0.53 |
| Ischemic Heart Disease | 55 (11.3) | 40 (72.7) | 15 (27.3) | 0.51 |
| Cerebrovascular Disease | 42 (8.6) | 33 (78.6) | 9 (21.4) | 0.15 |
| Arrhythmias (including atrial fibrillation) | 42 (8.6) | 32 (76.2) | 10 (23.8) | 0.28 |
| Active Cancer (including haematological) | 39 (8.0) | 18 (46.2) | 21 (53.8) | 0.0014* |
| COPD (Chronic Obstructive Pulmonary Disease) | 39 (8.0) | 24 (61.5) | 15 (38.5) | 0.30 |
| Dementia        | 38 (7.8)      | 30 (78.9)     | 8 (21.1)      | 0.16 |
| Heart Failure   | 37 (7.6)      | 28 (75.7)     | 9 (24.3)      | 0.35 |
| Obesity         | 33 (6.8)      | 20 (60.6)     | 13 (39.4)     | 0.29 |
| Psychotic Disorder | 14 (3.1) | 12 (85.7) | 2 (14.3) | 0.17 |

| Number of Comorbidities | Number of Comorbidities | Number of Comorbidities |
|-------------------------|-------------------------|-------------------------|
| 0                       | 99 (20.4)               | 73 (73.7)               | 26 (26.3) |
| 1                       | 151 (31.1)              | 99 (65.6)               | 52 (34.4) |
| 2                       | 116 (23.9)              | 82 (70.7)               | 34 (29.3) |
| Chronic hyponatremia | Overall | Survived | Died | P value |
|----------------------|---------|----------|------|---------|
| No                   | 270     | 173 (64.1) | 97 (35.9) |         |
| Yes                  | 25      | 13 (52.0) | 12 (48.0) |         |
| Unknown              | 190     | 147 (77.4) | 43 (22.6) |         |

**Investigations at presentation**

|                      | Overall | Survived | Died | P value |
|----------------------|---------|----------|------|---------|
| **Ref Range**        | Med (IQR) | Med (IQR) | Med (IQR) |         |
| International system of units (SI) |         |         |         |         |
| Adjusted Sodium, mmol/L | 135-145 | 137 (135-140) | 138 (134-141) | 0.3386 |
| Potassium, mmol/L     | 3.5-5.1 | 4.2 (3.9-4.6) | 4.3 (3.93-4.7) | 0.008 |
| Urea, mmol/L          | 2.9-8.2 | 6.2 (4-10.6) | 8.8 (5.7-14.8) | <0.0001* |
| Creatinine, µmol/L    | 65-111 (M) | 86 (69-128) | 104 (74-162) | <0.0001* |
| CRP, nmol/L           | 0 - 0.5 | 8.3 (4.0-16.2) | 11.7 (6.7-19.9) | <0.0001* |
| Albumin, g/L          | 35-50   | 37 (34-40) | 36 (33-38) | <0.0001* |
| Bilirubin, umol/L     | 0 - 21  | 8 (5-12) | 8 (5-12) | 0.44 |
| ALT, units/L          | 0-33    | 28.0 (19.8-45.3) | 26.5 (19.0-47.0) | 0.46 |
|                  | Baseline | Univariate Analysis | Bonferroni Correction |
|------------------|----------|---------------------|-----------------------|
|                  | Characteristics | Laboratory Investigations |                           |
|                  | Mean (Range) | Mean (Range) | Mean (Range) | p-value |
| Hemoglobin, g/L  | 127 (112-141) | 129 (114-142) | 123 (109-136) | 0.0096 |
| White blood cells x 10^9 / L | 7.3 (5.2-10.2) | 7.2 (5.22-9.8) | 7.7 (5.4 – 10.7) | 0.25 |
| Platelets x 10^9 / L | 219 (165-280) | 223-168-279 | 208 (147-289) | 0.38 |
| Neutrophil Count x 10^9 / L | 5.4 (3.7-8.0) | 5.2 (3.6-7.5) | 6.2 (3.87-9.00) | 0.04 |
| Lymphocyte Count x 10^9 / L | 1.0 (0.7-1.4) | 1.0 (0.793-1.44) | 0.8 (0.60 – 1.23) | 0.0004* |
| D-Dimer, ng/ml   | 598 (308-1665) | 658 (281-1520) | 804 (381-1898) | 0.33 |
| Ferritin, ng/mL  | 189 (88-560) | 178 (85.8-604) | 247 (95.5-510) | 0.52 |
| Creatinine Kinase (CK), units/L | 3.0-7.8 | 6.6 (5.6-8.2) | 6.3 (5.5-7.75) | 6.9 (5.95-9.10) | 0.0045 |
| Troponin-T HS, ng/ml | 0.017 (0.014-0.034) | 0.014 (0.014-0.028) | 0.028 (0.017-0.054) | <0.0001* |

Baseline characteristics of patients and univariate analysis of laboratory investigations at presentation.

* P<0.05. Bonferroni correction for comorbidities and laboratory investigations.
Table 2 – Univariable and multivariable associations of risk factors with in-hospital mortality among COVID-19 patients

| Risk Factor                  | Univariable Analysis | Multivariable Analysis |
|------------------------------|----------------------|------------------------|
|                              | HR 95% CI            | p-value                | aHR* 95% CI | p-value |
| Sodium status                |                      |                        |             |         |
| Normonatremia                | Ref.                 | Ref.                   |             |         |
| Hypernatremia                | 2.71 (1.28, 5.76)    | 0.009                  | 2.74 (1.16, 6.4) | 0.02 |
| Hyponatremia                 | 0.59 (0.14, 2.53)    | 0.48                   | 0.53 (0.12, 2.38) | 0.41 |
| Urea (mmol/L)                | 1.07 (1.02, 1.12)    | 0.01                   | 1.01 (0.94, 1.08) | 0.78 |
| Age                          | 1.03 (1.00, 1.05)    | 0.04                   | 1.04 (1.01, 1.07) | 0.007|
| Sex                          |                      |                        |             |         |
| Female                       | Ref.                 | Ref.                   |             |         |
| Male                         | 1.01 (0.51, 2.01)    | 0.98                   | 0.83 (0.39, 1.75) | 0.62 |
| Ethnicity                    |                      |                        |             |         |
| Other                        | Ref.                 | Ref.                   |             |         |
| White                        | 0.66 (0.32, 1.37)    | 0.27                   | 0.61 (0.28, 1.35) | 0.39 |
| Smoking status               |                      |                        |             |         |
| No                           | Ref.                 | Ref.                   |             |         |
| Yes                          | 1.26 (0.30, 5.35)    | 0.75                   | 2.00 (0.41, 9.69) | 0.39 |
| Ex-Smoker                    | 0.79 (0.35, 1.77)    | 0.57                   | 0.99 (0.41, 2.39) | 0.99 |
| Number of comorbidities      |                      |                        |             |         |
| present                      |                      |                        |             |         |
| 0                            | Ref.                 | Ref.                   |             |         |
| 1                            | 0.98 (0.37, 2.64)    | 0.97                   | 1.03 (0.36, 2.98) | 0.95 |
| 2                            | 1.17 (0.42, 3.23)    | 0.76                   | 1.05 (0.36, 3.07) | 0.93 |
| ≥3                           | 1.46 (0.54, 3.92)    | 0.45                   | 1.46 (0.50, 4.24) | 0.49 |
| CRP (mg/L)/20 units          | 1.06 (1.01, 1.11)    | 0.01                   | 1.10 (1.04, 1.17) | <0.001|

*aHR : adjusted hazard ratio
Figures

Figure 1 – Probability of death based on serum sodium values 2 days after admission

Kaplan-Meier curve showing probability of death based on serum sodium status 2 days after admission.

Patients with hypernatremia had a 2.34-fold increased risk of death compared to normonatremic patients.

** P <0.005.

Number at risk

| Sodium Status | 270 | 137 | 58 | 37 | 26 | 19 | 15 |
|---------------|-----|-----|----|----|----|----|----|
| Normonatremic |     |     |    |    |    |    |    |
| Hyponatremic  | 61  | 36  | 12 | 8  | 6  | 4  | 3  |
| Hyponatremic  | 27  | 10  | 4  | 3  | 3  | 1  | 1  |
Figure 2 - Probability of death based on history of abnormal serum sodium at any time during hospitalization

Kaplan-Meier curve showing probability of death based on exposure to abnormal sodium during hospitalization.

Patients with hypernatremia (red) or history of both hypernatremia and hyponatremia (purple) have had 3.05-fold and 2.25-fold increased risk of death compared to normonatremic patients.

*** P = 0.0038; **** p < 0.0001
Figure 3 – The progression of median serum sodium and urea levels during hospital stay

Values are expressed in median (95% confidence interval).

Sodium values are colored in black and urea values are colored in pink.

The inner bars represent the normal reference ranges for each parameter. Using the Friedman test, p value was <0.001 for sodium and 0.01 for urea change over the period of hospitalization.
Figure 4 – Median serum sodium and urea levels during hospitalization in survivors and non-survivors

Values are expressed in median (95% confidence interval).

Values for survivors are colored in green and for non-survivors in red.

The blue dotted lines show the upper and the lower reference limit for each parameter.

The magnitude of serum sodium increase was larger in non-survivors than in survivors.

The trajectory of serum urea was similar in survivors and non-survivors.